Table 2 Clinical and demographic characteristics of responders and non‐responders to antiviral therapy.
| Genotypes 1 and 4 (n = 66) | Genotypes 2 and 3 (n = 79) | |||||
|---|---|---|---|---|---|---|
| RES | NR | p Value | RES | NR | p Value | |
| No of patients | 30 (45%) | 36 (55%) | 62 (78%) | 17(22%) | ||
| Sex (% male) | 20 (67%) | 31 (86%) | 0.080* | 43 (69%) | 13 (76%) | 0.40* |
| Age (y) | 42.2 (1.3) | 43.7 (1.0) | 0.33† | 40.8 (1.1) | 45.5 (2.5) | 0.062† |
| Pretreatment biopsy | ||||||
| Cirrhosis | 2 (7%) | 14 (39%) | 0.003* | 6 (10%) | 2 (12%) | 0.58* |
| Steatosis | ||||||
| None | 17 (57%) | 15 (42%) | 19 (31 %) | 9 (53%) | ||
| Mild | 10 (33%) | 15 (42%) | 23 (37%) | 4 (24%) | ||
| Moderate/severe | 3 (10%) | 6 (17%) | 0.45‡ | 20 (32%) | 4 (24%) | 0.23‡ |
| BMI | ||||||
| Non‐obese | 29 (97%) | 25 (69%) | 55 (89%) | 13 (76%) | ||
| Obese | 1 (3%) | 11 (31%) | 0.004* | 7 (11%) | 4 (24%) | 0.24* |
| Fasting insulin (mU/l) | 9.71 (2.47) | 9.98 (1.50) | 0.92† | 8.45 (1.06) | 7.73 (1.06) | 0.75† |
| HOMA (mU/l) | 1.95 (0.045) | 2.31 (0.48) | 0.62† | 1.89 (0.26) | 1.68 (0.45) | 0.71† |
| C peptide (nmol/l) | 0.77 (1.79) | 0.86 (0.95) | 0.60† | 0.69 (0.56) | 0.56 (0.75) | 0.25† |
Data are mean (SEM).
NR, non‐response to antiviral treatment; RES, response to antiviral treatment; BMI, body mass index; HOMA, homeostasis model of assessment.
*Fisher's exact test; †Mann‐Whitney U test; ‡χ2 test.